首先恭賀中國農業大學使用恒遠生物自主品牌ELISA試劑盒在《Molecular Cancer》期刊上發表的SCI文獻——A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triplenegative breast cancer順利通過，IF影響因子高達37.3分！其次恭喜成功贏取了恒遠生物獎學金，同時感謝對我司產品的認可，希望以下文獻能幫助大家了解目前研究進展及我們的核心技術，歡迎各位老師聯系我們咨詢、提出意見，愿我們的努力成果與您的科研碰撞出不一樣的火花！

恒遠生物自主研發ELISA試劑盒，現已涵蓋20多個種屬，數千種產品，涉及腫瘤、激素、自身免疫、心血管、代謝等十多個研究領域。其ELISA試劑盒不僅檢測指標豐富，還可以根據實驗需求定制檢測范圍，并且提供實驗外包與免費代測服務。

恒遠產品文獻:人B細胞淋巴瘤因子2(Bcl-2)ELISA試劑盒引用文獻

【文獻標題】A novel polypeptide CAPG-171aa encoded by circCAPG plays a critical role in triplenegative breast cancer

【作者單位】中國農業大學(China Agricultural University)

【文獻中引用產品】

人B細胞淋巴瘤因子2(Bcl-2)ELISA試劑盒

【關鍵詞】TNBC, CircCAPG, CAPG-171aa, STK38, MEKK2, SLU7, Therapeutic target

【影響因子(IF)】37.3

【出版期刊】《Molecular Cancer》

【產品原文引用】Western blotting was performed by anti-MEKK2 (Proteintech, 55106-1-AP), MEK1/2 (ABclonal, A4868), SMURF1 (Bioss, bs-9391R), STK38 (Huabio, ER60144), ERK1/2 (Proteintech, 11257-1-AP), UB (Cell Signaling Technology, #3936), Phospho-MEK1/2 (Ser221) (Cell Signaling Technology, #2338), Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (Cell Signaling Technology, #8544), CAPG (Bioss, bsm-60,451 M), CDK4 (AtaGenix Laboratories Co., Ltd.(Wuhan), Wuhan, PR China, PA9437H), Cyclin D1 (Yeasen, 30026ES50), BCL2 (Shanghai hengyuan biological technology co., LTD, A-01203), CAPG (Proteintech, 10194-1-AP), FLAG (SMART, /smart-lifesciences, SLAB0101), HA (Yeasen, 30702ES20), HIS (Yeasen, 30401ES10). β-ACTIN, GAPDH, or TUBULIN (Proteintech, USA) were used as loading controls. All antibodies were diluted as required by the manufacturer (New Cell & Molecular Biotech, WB100D).

完整版PDF文獻請咨詢在線客服或者聯系我司業務員！

更多公司福利請關注“恒遠生物"微信公眾號！

或訪問恒遠生物